NEW YORK (GenomeWeb News) – Waters today said that revenues in the third quarter dropped about 1 percent year over year as foreign currency translation tamped down sales by 3 percent.

For the three months ended Sept. 29, Waters reeled in $450.0 million in total revenue, down from $454.5 million a year ago and short of consensus Wall Street estimates of $451.1 million.

According to Chairman, President, and CEO Douglas Berthiaume, Waters saw stable pharmaceutical demand as well as strong sales in Asia allowing the company to grow organically during the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: GWAS links gene to noise-induced hearing loss in mice, population genetics of malaria parasites, and more.

Nautilus' Alexandra Ossola examines how Tay-Sachs disease jump-started the genetic disease testing field.

FASEB says guidelines proposed by the NIH to bolster research reproducibility are premature and don't take the full range of scientific studies into consideration.

Liquid biopsies and DNA tests may be able to tell physicians whether a cancer patient is relapsing, the New York Times reports.